Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway
Journal of Natural Medicines · 2024
DOI: 10.1007/s11418-024-01821-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Natural Medicines, 2024. Verfasst von Haochi Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. Hauptthemen laut MEDLINE: Apoptosis, Cell Proliferation, Colorectal Neoplasms, Coumarins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.
Abstract (Originalsprache)
Urolithin families are gut-microbial metabolites of ellagic acid (EA). Although urolithin A (UA) and urolithin B (UB) were reported to have antiproliferative activities in cancer cells, the role and related mechanisms of urolithin C (UC) in colorectal cancer (CRC) have not yet been clarified. In this study, we assess the antitumor activities of UC in vitro and in vivo and further explore the underlying mechanisms in CRC cell lines. We found that UC inhibited the proliferation and migration of CRC cells, induced apoptosis, and arrested the cell cycle at the G2/M phase in vitro, and UC inhibited tumor growth in a subcutaneous transplantation tumor model in vivo. Mechanically, UC blocked the activation of the AKT/mTOR signaling pathway by decreasing the expression of Y-box binding protein 1(YBX1). The AKT agonist SC79 could reverse the suppression of cell proliferation in UC-treated CRC cells. In conclusion, our research revealed that UC could prevent the progression of CRC by blocking AKT/mTOR signaling, suggesting that it may have potential therapeutic values. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
- Department of Oncology and Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
- Department of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610047, China.
- Yu-Yue Pathology Scientific Research Centre, Chongqing, 400039, China.
- Jinfeng Laboratory, Chongqing, 401329, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
Zitieren
APA
Yang, H., Wu, B., Yang, Q., Tan, T., Shang, D., Chen, J., Cao, C., & Xu, C. (2024). Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway. Journal of Natural Medicines. https://doi.org/10.1007/s11418-024-01821-2
Vancouver
Yang H, Wu B, Yang Q, Tan T, Shang D, Chen J, et al. Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway. Journal of Natural Medicines. 2024. doi:10.1007/s11418-024-01821-2
BibTeX
@article{Yang2024,
author = {Yang, Haochi and Wu, Binghuo and Yang, Qi and Tan, Tian and Shang, Dan and Chen, Jie and Cao, Chenhui and Xu, Chuan},
title = {Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway},
journal = {Journal of Natural Medicines},
year = {2024},
doi = {10.1007/s11418-024-01821-2}
}
EUVIMED